Currently Viewing:
In Focus Blog
Currently Reading
Rise of Marijuana Cries Out for Research, Regulation, Physicians Say
January 07, 2019 – Mary Caffrey
Fentanyl Driving Overdose Deaths in the US, CDC Says
December 13, 2018 – Allison Inserro
Sanofi Pivotal Trial to Target Driver of Cyst Growth in PKD
November 12, 2018 – Mary Caffrey
Narrow Vote Calls for Keeping Drug Safety Trials, but Many See Changes
October 29, 2018 – Mary Caffrey
Joint Statement Released on Managing Hyperglycemia in Type 2 Diabetes
October 08, 2018 – Mary Caffrey
More Than 100-Fold Cost Differences Found for Pivotal Trials
September 26, 2018 – Jaime Rosenberg
MitraClip Reduces Hospital Stays, Deaths Among Patients With Heart Failure
September 24, 2018 – Mary Caffrey
Gottlieb Calls on Payers to Share Data to Aid Drug Innovation
June 25, 2018 – Mary Caffrey
How Can Public Health, Traditional Healthcare Transform Community Wellness?
June 18, 2018 – Allison Inserro

Rise of Marijuana Cries Out for Research, Regulation, Physicians Say

Mary Caffrey
Research and regulatory gaps in the use of marijuana will only grow unless the scientific community and policy leaders fill the void, according to a commentary series in Annals of Internal Medicine on marijuana’s rising availability.
What are the consequences of making marijuana available? Doctors from the University of Colorado share this account from the emergency department (ED):

A decade ago, they write in the Annals of Internal Medicine,1 a child with marijuana exposure was a rare event. After the federal government minimized enforcement of the state’s medical marijuana law in 2009, children began showing up in the ED at the state’s largest pediatric hospital, mostly after consuming products containing marijuana, or cannabis. Eight children were hospitalized in 14 months. There had been no hospitalizations in the previous 4 years.

“These hospitalizations are almost always due to unintentional, unsupervised ingestion of an edible product containing cannabis, such as candy or baked goods,” the Colorado doctors write in a special commentary section of Annals on marijuana’s rising availability, published today. “We still see several each month.”

The opioid crisis has left patients and physicians looking for alternatives to treat pain, reduce anxiety, and improve sleep. Today, 34 states allow medical marijuana and 10 permit recreational use, but gaps in evidence put physicians and insurers in a bind. When should marijuana be prescribed? What doses are appropriate? And will marijuana ever be covered by insurance?

Research and regulatory gaps will only grow unless the scientific community and policy leaders fill the void, according to the commentary series in Annals, the official journal of the American College of Physicians, which represents both primary care physicians and specialists.

Authors from the Center for Preventive Cardiology at the Oregon Health and Sciences University (OHSU) highlight the urgency for policy makers: They cite data that show a 455% increase in marijuana use from 2002 to 2014 among adults aged 55 to 64 years and a 333% increase among those 64 years or older—the population eligible for Medicare or close to it. “Health providers often do not ask for a history of marijuana use, and—depending on state laws—patients may not always be forthcoming in disclosing it,” they write. Thus, it’s important for doctors to ask about marijuana use in a nonjudgmental way.2

Editors of Annals received more than 100 manuscripts from readers about aspects of prescribing or recommending marijuana, and the 6 commentaries selected address both medical and recreational use:
  • A paper from the University of Pittsburgh Medical Center (UPMC) Health Plan outlines the “conundrum” surrounding marijuana: There is great interest among physicians, insurers, and patients in using cannabis products instead of opioids for pain relief, but “much of [the] evidence is observational or anecdotal,” instead of the gold standard of a clinical trial.3
  • Like the UPMC Health Plan authors, Jan K. Carney, MD, MPH, of the University of Vermont, writes about the lack of standardization of the product. She notes supplies in federally sanctioned research projects “may be less potent than state products, creating an environment where research findings—even if experiments are rigorously conducted—may not mirror real-world outcomes.”4
  • Kevin P. Boehnke, PhD, and Daniel J. Clauw, MD, of the University of Michigan Medical School, describe dosing with cannabidiol, the component of cannabis that is not intoxicating. They say this should be used alone before adding tetrahydrocannabinol, commonly known as THC. Neither, however, is a first-line treatment before opioids, the authors say.5
  • When it comes to what forms of marijuana are best for medical use, various papers recommended drops or edibles, or vaping instead of smoking. In June 2018, the FDA approved Epidiolex (cannabidiol) oral solution for the treatment of seizures associated with 2 rare and severe forms of epilepsy. It was the first FDA-approved drug that contained a purified drug substance derived from marijuana.
  • While the papers saw potential for medical marijuana, both Carney and the OHSU authors discussed the potential harms of recreational use. Carney cited survey data to show that 30% of the public now believes marijuana prevents health problems, while the OHSU authors highlighted a 1988 study in the New England Journal of Medicine that found that smoking marijuana restricted oxygen flow through body at 5 times the rate of tobacco.
  • As marijuana goes mainstream, more women are smoking it during pregnancy and while breastfeeding, despite the lack of evidence this is safe for the baby. Absent clinical trials, marijuana and its components should be avoided by pregnant women and nursing mothers, writes Eli Y. Adashi, MD, MS.6

Related Articles

Seeking Sensible Cannabis Policy Requires "Balance," Says Beth Israel's Hill
Dr Kevin Hill: Policy Is Ahead of Science on Medical Cannabis
Medical Marijuana in Cancer Treatment: No Standards of Care, and So Far, No Coverage
Considerations for Clinicians Looking to Advise Patients About Cannabis
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up